Efficacy and safety of adding mizoribine to standard treatment in patients with immunoglobulin A nephropathy: A randomized controlled trial

• Asıl Yazarlar: Keiji Hirai (Yazar), Susumu Ookawara (Yazar), Taisuke Kitano (Yazar), Haruhisa Miyazawa (Yazar), Kiyonori Ito (Yazar), Yuichirou Ueda (Yazar), Yoshio Kaku (Yazar), Taro Hoshino (Yazar), Honami Mori (Yazar), Izumi Yoshida (Yazar), Kenji Kubota (Yazar), Yasuyoshi Yamaji (Yazar), Tetsuro Takeda (Yazar), Yoshikazu Nakamura (Yazar), Kaoru Tabei (Yazar), Yoshiyuki Morishita (Yazar)
• Materyal Türü: Kitap
• Baskı/Yayın Bilgisi: The Korean Society of Nephrology, 2017-06-01T00:00:00Z.
• Konular: article
• Online Erişim: Connect to this object online.

Background: Mizoribine (MZR) is an immunosuppressive drug used in Japan for treating patients with lupus nephritis and nephrotic syndrome and has been also reportedly effective in patients with immunoglobulin A (IgA) nephropathy. However, to date, few randomized control studies of MZR are performed...